Vise Technologies Inc. Makes New Investment in Sotera Health Company $SHC

Vise Technologies Inc. acquired a new stake in shares of Sotera Health Company (NASDAQ:SHC) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 13,337 shares of the company’s stock, valued at approximately $148,000.

Other hedge funds also recently made changes to their positions in the company. TPG GP A LLC purchased a new stake in Sotera Health in the 1st quarter worth approximately $79,126,000. Sculptor Capital LP boosted its position in shares of Sotera Health by 80.8% in the first quarter. Sculptor Capital LP now owns 9,037,511 shares of the company’s stock worth $105,377,000 after purchasing an additional 4,037,511 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Sotera Health by 5.9% in the first quarter. T. Rowe Price Investment Management Inc. now owns 8,045,502 shares of the company’s stock worth $93,811,000 after purchasing an additional 450,761 shares in the last quarter. Two Seas Capital LP raised its position in shares of Sotera Health by 14.7% during the 1st quarter. Two Seas Capital LP now owns 3,321,136 shares of the company’s stock valued at $38,724,000 after purchasing an additional 425,000 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Sotera Health during the 1st quarter valued at $4,433,000. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Price Performance

NASDAQ:SHC opened at $15.23 on Wednesday. The business’s 50-day moving average is $16.08 and its 200 day moving average is $14.01. Sotera Health Company has a 12 month low of $9.53 and a 12 month high of $17.78. The company has a market capitalization of $4.33 billion, a P/E ratio of 80.16 and a beta of 1.82. The company has a current ratio of 2.38, a quick ratio of 2.18 and a debt-to-equity ratio of 4.04.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The business had revenue of $311.31 million during the quarter, compared to analysts’ expectations of $303.63 million. Sotera Health had a return on equity of 43.69% and a net margin of 4.82%. Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. On average, equities research analysts forecast that Sotera Health Company will post 0.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Michael P. Rutz sold 126,611 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $16.38, for a total transaction of $2,073,888.18. Following the sale, the insider owned 450,204 shares of the company’s stock, valued at $7,374,341.52. This represents a 21.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gtcr Investment Xi Llc sold 12,000,000 shares of Sotera Health stock in a transaction on Monday, November 10th. The stock was sold at an average price of $15.65, for a total transaction of $187,800,000.00. Following the completion of the transaction, the director directly owned 29,215,301 shares of the company’s stock, valued at $457,219,460.65. The trade was a 29.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 32,126,611 shares of company stock worth $492,073,888. Insiders own 55.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Barclays increased their price target on Sotera Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Piper Sandler increased their target price on Sotera Health from $15.00 to $17.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. BMO Capital Markets initiated coverage on Sotera Health in a research note on Thursday, November 13th. They set an “outperform” rating and a $19.00 target price on the stock. Wall Street Zen upgraded Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings upgraded shares of Sotera Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.67.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.